James L. Murray - Concepedia

Author

James L. Murray

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

J L MURRAY, J L Murray, J Murray, J. L. MURRAY, J. L. Murray, J. Lee Murray, J. Murray, J.L. Murray, JAMES L. MURRAY, James L Murray

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Breast Cancer Care University of Louisville James Graham Brown Foundation

About

James L. Murray is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	288
2	Health Sciences	3	3	52
3	Natural Sciences	3	3	106
4	Biochemistry	2	2	74
5	Engineering	1	1	16

James L. Murray

Publications

701

Citations

H-Index

Page 1

	Year	Citations
Lipid Bilayer Simulations of CXCR4 with Inverse Agonists and Weak Partial Agonists John O. Trent, Zixuan Wang, James L. Murray, Journal of Biological Chemistry	2003	115
Phase II radioimmunotherapy trial with131I-CC49 in colorectal cancer James L. Murray, Daniel J. Macey, Leela P. Kasi, Cancer	1994	88
Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization 1 1Edited by I. Wilson Qinxue Hu, John O. Trent, Georgia D. Tomaras, Journal of Molecular Biology Molecular CharacterizationBiochemistryNatural SciencesMolecular BiologyCcr5 Utilization 1	2000	57
Metastatic Tumor to the Retina and Vitreous Cavity from Primary Melanoma of the Skin Dennis M. Robertson, C. P. Wilkinson, James L. Murray, Ophthalmology Metastatic TumorVitreous BodyVitreous CavitySurgical PathologyMelanoma	1981	56
Phase I and II Study of Exisulind in Combination With Capecitabine in Patients With Metastatic Breast Cancer Lajos Pusztai, Jim Hou Zhen, Banu Arun, Journal of Clinical Oncology	2003	54
Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. M. G. Rosenblum, Claire F. Verschraegen, James L. Murray, PubMed Endocrine-related CancerMedicineMetronomic TherapyPharmacologyImmunology	1999	52
Estimated median survival times of patients with colorectal cancer based on experience with 9,745 patients Debra T. Silverman, James L. Murray, Charles R. Smart, The American Journal of Surgery Surgical OncologyMedicinePrognosisColorectal CancerOutcomes Research	1977	40
An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models Michael G. Rosenblum, Lawrence H. Cheung, Kalpana Mujoo, Cancer Immunology Immunotherapy InflammationImmunotoxicologyTissue DispositionXenograft ModelsMelanoma	1995	38
Clinical Pharmacology, Metabolism, and Tissue Distribution of 90Y-Labeled Monoclonal Antibody B72.3 After Intraperitoneal Administration M. G. Rosenblum, J. J. Kavanagh, Thomas W. Burke, JNCI Journal of the National Cancer Institute	1991	37
A Role for H/ACA and C/D Small Nucleolar RNAs in Viral Replication James L. Murray, Jinsong Sheng, Donald H. Rubin Molecular Biotechnology ChromatinViral ReplicationNatural SciencesMolecular BiologyVirology	2014	33

Page 1